Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Jul 22;106(6):1310–1318. doi: 10.1002/cpt.1534

Figure 1.

Figure 1.

Enrollment and completion of intensive PK studies from trials evaluating DHA- piperaquine as IPTi for malaria; DP denotes DHA-piperaquine; SP, sulfadoxine-pyrimethamine; PK, pharmacokinetics; DHA, dihydroartemisinin; PQ, piperaquine. *Adult data previously reported (14).